Akeso (HKG:9926) swung to an attributable loss of 514.5 million yuan in 2024 from a profit of 2.03 billion yuan in 2023, according to a Sunday filing with the Hong Kong bourse.
The biopharmaceuticals producer swung to a loss per share of 0.60 yuan from earnings per share of 2.42 yuan in the previous year.
Revenue declined 53% to 2.12 billion yuan from 4.53 billion yuan a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.